通过共同靶向中性粒细胞-骨髓来源的抑制性细胞增强泌尿生殖系统恶性肿瘤的免疫检查点阻断治疗
Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs.
作者信息
Lu Xuemin, Lu Xin
机构信息
Department of Biological Sciences, Boler-Parseghian Center for Rare and Neglected Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Department of Biological Sciences, Boler-Parseghian Center for Rare and Neglected Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA; Tumor Microenvironment and Metastasis Program, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA.
出版信息
Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188702. doi: 10.1016/j.bbcan.2022.188702. Epub 2022 Feb 25.
Immune checkpoint blockade (ICB) as a powerful immunotherapy has transformed cancer treatment. The application of ICB to genitourinary malignancies has generated substantial clinical benefits for patients with advanced kidney cancer or bladder cancer, yet very limited response to ICB therapy was observed from metastatic castration-resistant prostate cancer. The efficacy of ICB in rare genitourinary tumors (e.g. penile cancer) awaits results from ongoing clinical trials. A potential barrier for ICB is tumor-infiltrating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) with their functions and mechanisms recently revealed. Preclinical studies suggest that successful therapeutic inhibition of PMN-MDSCs synergizes effectively with ICB to eradicate ICB-refractory genitourinary malignancies.
免疫检查点阻断（ICB）作为一种强大的免疫疗法，已经改变了癌症治疗方式。ICB在泌尿生殖系统恶性肿瘤中的应用已为晚期肾癌或膀胱癌患者带来了显著的临床益处，但转移性去势抵抗性前列腺癌对ICB治疗的反应却非常有限。ICB在罕见泌尿生殖系统肿瘤（如阴茎癌）中的疗效有待正在进行的临床试验结果。ICB的一个潜在障碍是肿瘤浸润的多形核髓源性抑制细胞（PMN-MDSC），其功能和机制最近已被揭示。临床前研究表明，对PMN-MDSC的成功治疗性抑制与ICB有效协同作用，以根除对ICB难治的泌尿生殖系统恶性肿瘤。
Zotero 插件